Compare 10X Genomics Inc (TXG) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Wheaton Precious Metals Corp — how do they compare? 10X Genomics Inc trades at $80.1 (market cap $9.92B), while Wheaton Precious Metals Corp trades at $138.2 (market cap $60.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 6.1× 10X Genomics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Wheaton Precious Metals Corp for 66 Days on average.
| TXG | WPM | |
|---|---|---|
Market Cap | $9.92B | $60.84B |
Volume | 9,372,166 | 1,408,370 |
Sector | Health | Basic Materials |
52-Week High | $97.74 | $165.72 |
52-Week Low | $11.48 | $94.37 |
Typical Hold Time | 92 Days | 66 Days |
Enterprise Value | $9.44B | $62.71B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Wheaton Precious Metals (WPM) trades at $134.96, down 1.95% on the day, amid a bearish technical signal. The company reported record revenues of $2.31B in 2025, with net income surging to $1.47B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive with strong analyst support—80% recommend Buy and a consensus price target of $164.80 implies 22% upside. Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock's current valuation multiples are elevated, but robust cash flow and margin expansion underpin the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
